The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Medical Innovation in the Changing Healthcare Marketplace: Conference Summary
Lichtenberg, Frank R. 1996. Do (more and better) drugs keep people out of the hospital? American Economic Review (May):384-388.
Lichtenberg, Frank R. 2001. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs 20(5):241-251.
Mark, Daniel B., Mark A. Hlatky, Robert M. Califf, C. David Naylor, Kerry L. Lee, Paul W. Armstrong, Gabriel Barbash, Harvey White, Maarten L. Simoons, Charlotte L. Nelson, Nancy Clapp-Channing, J. David Knight, Frank E. Harrell, John Simes, and Eric J. Topol. 1995. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New Eng J. of Med. 332(21):1418-1424.
Robinson, James C. 2001. The End of Managed Care. JAMA 285(20):2622-2628.
Tolley, George, Donald Kenkel, and Robert Fabian, (eds). 1994. Valuing Health for Policy: An Economic Approach. Chicago: The University of Chicago Press.
Topel, Robert H., and Kevin M. Murphy. Forthcoming. The Economic Value of Medical Knowledge. In: Exceptional Returns, Robert H. Topel and Kevin M. Murphy, eds. Chicago: University of Chicago Press.
Viscusi, W. Kip. 1993. The value of risks to life and health. Journal of Economic Literature, 31(4):1912-1946.
Washington Post editorial. June 9, 2001. Back to health care costs.